Skip to main content
Clinical Trials/NCT05694455
NCT05694455CompletedNot Applicable

Clinical Utility of Longitudinal Measurement of Hemodynamic Incoherence and Endothelial

Denver Health and Hospital Authority2 sites in 1 country68 target enrollmentStarted: July 1, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
68
Locations
2
Primary Endpoint
Initiation and Duration Renal Replacement Therapy

Study Overview

Brief Summary

Purpose: To assess the prognostic role of Handheld Vital Microscopy (HVM) and evaluate levels of endothelial glycocalyx (eGC) breakdown in patients demonstrating Hemodynamic Incoherence (HI), to elucidate a mechanistic link between the eGC and HI in order to inform prognostic enrichment of future resuscitation trials. We will serially evaluate microhemodynamics (MiH) and macro hemodynamics (maH) and the perfused boundary region (PBR, an visual proxy for eGC thickness) using HVM, and a validated circulating biomarker of eGC integrity.

Detailed Description

There are few reliable prognostic indicators in early sepsis to predict disease progression, in part because the pathophysiologic mechanism of vascular dysregulation remains incompletely understood. The global Coronavirus Disease 2019 (COVID-19) pandemic has increased the number of patients with sepsis, straining hospital systems and illustrating the need for research into prognostic and therapeutic strategies. An important area of research is the role of the eGC, a thin vascular lining composed of proteoglycans, glycosaminoglycan side-chains, and plasma proteins that play a central role in microvascular homeostasis, the function of which is compromised in sepsis. Another growing field of inquiry is the phenomenon of HI, a condition in which MiH remain dysfunctional despite normalization of conventionally targeted MaH measures such as mean arterial pressure (MAP), leading to poor end-organ perfusion. It has been hypothesized that HI due to persistently deranged MiH and reduced end-organ perfusion result in an ongoing state of "microvascular shock", leading to worsening end-organ damage despite apparent normalization of conventionally targeted parameters. Importantly, HI has been shown to predict poor patient outcomes, with abnormal MiH predicting patient mortality despite normalization of MAP after administration of vasoactive medications. MiH measures have also been shown to differ significantly between septic patients and healthy controls. In one study of a large sepsis cohort, MiH parameters were predictive of adverse outcomes, while MaH parameters were not, suggesting that MiH measurements, and HI in particular may be more sensitive than conventional measures for predicting outcomes in sepsis. One hypothesis is that HI in sepsis is mediated by degradation of the eGC, with subsequent loss of microvascular homeostasis, though the role of the eGC as a vascular barrier remains controversial.

One question that remains is whether or not microvascular changes can predict patient outcomes in patients judged to be adequately fluid resuscitated, as measured by MAP or Starling Stroke Volume/Non-invasive cardiac monitor (NICOM) testing.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Septic Patient Cohort:
  • Greater than or equal to 18 years of age
  • Diagnosed with sepsis or septic shock
  • Require admission to the Hospital
  • Control Cohort:
  • Greater than or equal to 18 years of age
  • Undergoing elective surgery requiring intubation and general anesthesia

Exclusion Criteria

  • Patients with any of the following characteristics will be excluded
  • Less than 18 years old
  • Chronic Kidney disease on dialysis
  • Currently pregnant
  • Incarcerated persons
  • Control Cohort:
  • Less than 18 years old
  • History of Chronic Kidney disease on dialysis, uncontrolled diabetes, cirrhosis, heart failure, or nephritic or nephrotic syndromes.
  • Currently pregnant
  • Incarcerated persons

Arms & Interventions

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

Intervention: Starling Stroke Volume (Starling SV)- Passive Leg Raise (Diagnostic Test)

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

Intervention: Microscan Sublingual Microscopy (Diagnostic Test)

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

Intervention: Venous Excess Ultrasound Scoring (VExUS) (Diagnostic Test)

Control Patient Interventions

Other

Control patients will have urine collection and sublingual microscopy performed when intubated

Intervention: Starling Stroke Volume (Starling SV)- Passive Leg Raise (Diagnostic Test)

Control Patient Interventions

Other

Control patients will have urine collection and sublingual microscopy performed when intubated

Intervention: Urine Collection (Other)

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

Intervention: Urine Collection (Other)

Outcomes

Primary Outcomes

Initiation and Duration Renal Replacement Therapy

Time Frame: 90 day

Renal Replacement Therapy will be monitored while hospitalized for Sepsis/Septic Shock for initiation and days receiving Renal replacement will be counted.

Secondary Outcomes

  • Rate of Inpatient Mortality(90 day)
  • Rate of 90 day survival(90 day)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ivor Douglas

Chief Pulmonary Critical Care

Denver Health and Hospital Authority

Study Sites (2)

Loading locations...

Similar Trials